|
SLC30A5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.77859973813111E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.21909999767556E-08 |
| Normal-vs-Stage2 |
4.0047000000043E-05 |
| Normal-vs-Stage3 |
8.22619972140615E-10 |
| Normal-vs-Stage4 |
8.60200000118994E-08 |
| Stage1-vs-Stage2 |
7.352800E-01 |
| Stage1-vs-Stage3 |
8.816000E-02 |
| Stage1-vs-Stage4 |
2.466000E-01 |
| Stage2-vs-Stage3 |
4.167200E-01 |
| Stage2-vs-Stage4 |
5.446800E-01 |
| Stage3-vs-Stage4 |
8.925000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.50160045193127E-10 |
| Normal-vs-AfricanAmerican |
4.196900E-03 |
| Normal-vs-Asian |
5.87000000051852E-07 |
| Caucasian-vs-AfricanAmerican |
2.681200E-01 |
| Caucasian-vs-Asian |
9.216000E-01 |
| AfricanAmerican-vs-Asian |
2.519800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.21849996759238E-09 |
| Normal-vs-Female |
5.93930005177157E-09 |
| Male-vs-Female |
2.332200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.30689999950407E-07 |
| Normal-vs-Age(41-60Yrs) |
2.4970999712437E-09 |
| Normal-vs-Age(61-80Yrs) |
9.6114000092129E-09 |
| Normal-vs-Age(81-100Yrs) |
6.978000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.329400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.120000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.014400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.977000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.935600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.277400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.289990E-02 |
| Classical-VS-Follicular |
6.406400E-02 |
| Classical-VS-Other |
1.836180E-01 |
| Classical-VS-Normal |
7.92019999584781E-08 |
| Tall-VS-Follicular |
4.299200E-01 |
| Tall-VS-Other |
7.341600E-01 |
| Tall-VS-Normal |
2.35589999730834E-08 |
| Follicular-VS-Other |
5.553600E-01 |
| Follicular-VS-Normal |
1.7160999998822E-07 |
| Other-VS-Normal |
1.844720E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.2106999958128E-08 |
| Normal-vs-N1 |
1.69739999944518E-07 |
| N0-vs-N1 |
5.124800E-01 |
|
|
